CDC data shows that mortality from heart failure-related cardiac arrest has decreased significantly in the last 25 years. However, researchers noted, care teams still have considerable work to do.

Researchers explored data from nearly 80,000 patients, comparing the newest clot-busting stroke drug from Genetech with its predecessor.

Multiple women have come forward with similar allegations against the Texas cardiologist. Police believe there may be additional victims as well.

A Florida family is suing Mayo Clinic for allegedly performing a heart transplant without communicating certain risks associated with the donated organ. Mayo Clinic has pushed back against those claims, saying it acted appropriately every step of the way. 

Caristo Diagnostics, an Oxford-based medtech company founded by cardiologists, has gained FDA clearance for its CaRi-Plaque technology.

The donor-derived cell-free DNA tests from CareDx are designed to limit the use of surveillance biopsies and other more invasive treatment options. These tests have been available for adult patients for years now.

New technology now being considered by the FDA for approval can capture coronary inflammation on CCTA images and provide risk assessments. What could this mean for the future of cardiac care? We spoke to one researcher to learn more.

Kestra Medical Technologies, known for its wearable heart monitors and defibrillators, intends to sell 10 million common shares priced somewhere between $14 and $16 per share. 

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Pinehurst Radiology Associates recently gave notice of the incident, launching an investigation amid suspicious activity on its network. 

It’s no surprise Trump Administration II is taking a laissez-faire stance toward AI regulation. After all, the winning candidate campaigned pretty hard on scaling back all regulation.